China's medical products administrator accepted Ocumension Therapeutics' (HKG:1477) phase 3 clinical trial application for its OT-802 pilocarpine hydrochloride drug for presbyopia or loss of focus of the eye.
The drug showed a favorable safety profile in preclinical studies, according to a Tuesday filing with the Hong Kong bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.